13 results about "Transplanted kidney" patented technology

The invention relates to a renal transplantation post-operation rejection risk monitoring and early warning method and a renal transplantation post-operation rejection risk monitoring and early warning system. The method comprises the steps of collecting recipient nursing monitoring data, laboratory indexes and transplanted kidney ultrasonic blood flow parameters in a follow-up visit period, performing timestamp alignment, deletion processing and standardization on multi-source data, extracting features to construct a time sequence feature sequence, inputting the time sequence feature sequence into a pre-training risk prediction model, outputting the rejection reaction occurrence probability of the next period, and forming a risk trend. Calculating a nursing sensitive index contribution weight based on the model contribution information, and screening a target nursing monitoring index; and establishing an individualized baseline model to obtain a baseline value and an allowable fluctuation interval, extracting characteristics such as deviation amplitude, direction, rate, fluctuation and continuous deviation duration and the like, and performing individualized calibration on the occurrence probability to obtain a calibration risk score. When the threshold value is not reached and the trend is not triggered, generating a nursing monitoring suggestion of the next period; and pushing early warning and generating grading intervention suggestions when a threshold value is reached or a trend is triggered.

The invention relates to the technical field of medical instruments, and discloses a disposable simple in-vitro transplantation renal artery perfusion apparatus which comprises a buckle seat, a panel and a perfusion tube, a perfusion tube mounting hole is formed in the middle of the panel, the perfusion tube is connected in the perfusion tube mounting hole in the middle of the panel in a penetrating mode, one end of the perfusion tube is connected with a perfusion tube, and the other end of the perfusion tube is connected with a drainage tube. The other end is inserted into the abdominal aorta; the buckle base comprises a bottom plate and side plates arranged at the two ends of the two sides of the bottom plate, a penetrating hole is formed in the middle of the bottom plate, and clamping grooves are formed in the inner sides of the side plates. The disposable simple in-vitro transplantation renal artery perfusion apparatus can be effectively fixed at an opening of an artery, perfusion can be carried out by connecting an infusion tube, assistance of other people is not needed, fixation is good, perfusate cannot leak out to cause waste, and intima of the artery cannot be damaged to cause series complications.

This invention discloses the application of quinolinic acid in the preparation of drugs for the prevention and treatment of acute kidney injury (AKI). AKI refers to acute kidney injury induced by renal ischemia-reperfusion. The drug is an oral formulation used for prophylactic administration in high-risk individuals undergoing iatrogenic procedures at potential AKI risk, and for pretreatment of ischemic conditions in transplanted kidneys. Experiments have shown that administration of quinolinic acid significantly reduces serum urea nitrogen levels in AKI mice, alleviates renal tissue morphological damage in AKI mice, and reduces the expression level of the renal tubular injury factor NGAL protein in AKI mice, demonstrating significant clinical value in the prevention and treatment of AKI.

Systems and methods for identifying risk of kidney graft failure in a subject are provided. An image of a graft biopsy is obtained, the image representing at least a subset of a plurality of morphological classes including a tissue compartment and inflammation class. The image is inputted into a trained model that identifies, as output, for each morphological class in at least the subset, corresponding objects in the image that fall within the morphological class. For each morphological class, corresponding digital features are generated comprising a first subset of individual feature scores obtained using the objects for the morphological class and a second subset of composite feature scores obtained by combining individual feature scores. Digital features for each morphological class are compared to a reference criterion, thus determining risk of kidney graft failure.

The invention discloses application of nintedanib in preparation of a medicine for treating plant migration and plant mineralization, and belongs to the technical field of biological medicine. The research shows that the nintedanib has the effects of reducing deposition of extracellular matrix of an allogeneic kidney transplantation model mouse, improving renal tubular atrophy, relieving mouse CD206 + macrophage infiltration and reducing rejection injury degree and immune infiltration degree of kidney grafts after being administered under the administration dosage without generating liver and kidney toxicity and intestinal side effects; the lesion process of mouse chronic transplanted kidney rejection is obviously slowed down, and the damage of excessively activated inflammatory cells to the transplanted kidney is reduced. The results show that nintedanib can delay the progress of chronic transplantation renal fibrosis.

The invention discloses application of alpha-ketoglutaric acid in preparation of a medicine for preventing and / or treating antibody-mediated rejection reaction, and belongs to the technical field of biological medicine. According to the application, an acute antibody-mediated rejection reaction model of mouse skin pre-sensitization combined with kidney transplantation is constructed, and alpha-KG is applied for intervention. Results show that the alpha-KG can significantly improve renal functions (serum creatinine and urea nitrogen are reduced), prolong survival time of the transplanted kidney, relieve histological injury of the transplanted kidney (Banff score is reduced), inhibit deposition of complement C3d, reduce the level of a specific antibody (DSA) of a peripheral blood donor, down-regulate expression of kidney local inflammatory factors (Tnf, Il-6, Il-1beta and Nos2), regulate immune cell infiltration in the transplanted kidney, and improve the survival rate of the transplanted kidney. Comprising the steps of reducing transplantation kidney mononuclear / macrophage infiltration, reducing the proportion of transplantation kidney pro-inflammatory macrophages and increasing the proportion of repair macrophages. The application provides a new drug choice for treating the acute antibody-mediated rejection of the transplanted kidney, and has an important clinical application prospect.

Provided herein are methods and compositions for treating kidney-related disease conditions and complications, such as Berger's disease, and for preventing transplant rejection. For example, the present disclosure describes a method of improving function of a transplanted kidney in a subject in need thereof, wherein the method comprises administering to the subject a therapeutically effective amount of an antibody or antigen-binding fragment thereof that specifically binds CD40 ligand.

This invention relates to a diagnostic kit for assessing transplant rejection status, belonging to the field of biomedical technology. The invention obtains data on the relative proportions and absolute counts of various immune cell populations in peripheral blood, and measures the ultrasound hemodynamic parameters of the transplanted kidney, including the interlobar artery resistance index and the renal aortic resistance index. It then uses the formula y1 = -1.228a + 0.008b – 0.009c to determine whether acute rejection exists. In the formula, the donor kidney type is defined as variable a, with living donor kidney = 0 and deceased donor kidney = 1; the absolute value of peripheral blood CD4 is defined as a continuous variable b; the absolute value of peripheral blood CD8 is defined as a continuous variable c; and when y1 > 0.5, acute rejection is determined. This invention makes the diagnosis of the immune status of transplanted kidneys non-invasive, optimizing the kidney transplant diagnosis and treatment process.

The invention relates to the technical field of biosensors and wireless health monitoring, and particularly discloses a renal rejection monitoring system based on a wireless implantable biosensor. The system comprises a wireless implantable biosensor array, an in-vivo signal preprocessing unit, an in-vitro data receiving and synchronizing device, a multi-modal heterogeneous data fusion engine and a space-time diagram neural network prediction model, immune and metabolism multi-dimensional biomarkers are collected around a transplanted kidney in real time, a dynamic'immunity-metabolism 'knowledge graph is constructed, and accurate prediction and graded early warning of rejection risks are achieved by means of space cascading and time evolution laws of time-space diagram neural network modeling signals. By the adoption of the technical scheme, sub-clinical rejection signals can be recognized before conventional indexes such as creatinine are abnormal, a window is intervened in advance, meanwhile, long-term non-invasive monitoring is achieved through wireless low-power-consumption design, and the accuracy and the intelligent level of postoperative management are improved.

This invention relates to the application of reagents for detecting biomarkers in the preparation of non-invasive diagnostic products for renal interstitial fibrosis and chronic progressive injury, belonging to the field of biotechnology. The biomarkers are SNX3, VPS4B, and SMO, derived from urinary extracellular vesicles, and their expression levels increase with the degree of transplanted kidney fibrosis. The urinary extracellular vesicle separation method of this invention effectively removes urinary glomerulonephrine entangled with vesicles during ultracentrifugation without affecting the structural integrity of the extracellular vesicles or the expression of the marker proteins. The biomarkers of this invention have excellent diagnostic capabilities for transplanted kidney fibrosis and also demonstrate outstanding ability in diagnosing chronic progressive injury of transplanted kidneys, predicting the risk of transplanted kidney failure, and assessing renal fibrosis in chronic kidney disease. They possess advantages such as good stability, high specificity, and high sensitivity, and are simple to operate with a short detection cycle, enabling non-invasive diagnosis or prognostic monitoring of fibrosis in both transplanted and non-transplanted kidneys.

A method of use of a synthetic SCGB, and compositions thereof, to prevent the development or reduce the development of antibodies against a foreign antigen or set of antigens in the subject that receives the antigen(s) is provided. A synthetic SCGB being recombinant human CC10 protein is provided. The foreign antigen(s) is / are a cell, tissue or organ from a donor subject is administered, introduced, or transplanted into a recipient subject, a lung transplant, transplanted kidney, heart, liver, hematopoietic cell, or any other tissue or organ, antigen(s) is / are from human or non-human origin, purified therapeutic proteins or other drugs, food or drink, self-antigen or an allergen.

The present application describes and claims a novel method for identifying and stratifying the risk of developing a BK virus nephropathy (“Nx BK-v” below) in patients having undergone a kidney transplant. This method uses an index combining at least three bio-markers: i) the intensity of the anti-BK-v memory T lymphocyte response (memory T lymphocytes which are specific to BK-v, hereinafter “LTm anti-BK-v”), ii) the number of occurrences of incompatibility in the HLA alleles of class I and class II between the donor and the recipient of the graft, taking into account iii) the viral charge of the BK-v virus in the whole blood of the patient. The present method allows a very precise evaluation of the risk of developing an Nx BK-v during the months following the test with the aim of optimising the immuno-suppressive treatment in order to better preserve the transplanted kidney.

Methods for assessing the likelihood of delayed graft function (DGF) of a donor kidney in a kidney transplant recipient are provided. Additionally, methods for determining the likelihood of requiring dialysis in a kidney transplant recipient are provided. Such methods include measuring expression of at least one gene in a sample from the kidney for transplant or from the transplanted kidney.